Pressure BioSciences (OTCMKTS:PBIO) & TransMedics Group (NASDAQ:TMDX) Head to Head Contrast

Pressure BioSciences (OTCMKTS:PBIO) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Profitability

This table compares Pressure BioSciences and TransMedics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pressure BioSciences	N/A	N/A	N/A
TransMedics Group	27.04%	22.38%	8.46%

Earnings & Valuation

This table compares Pressure BioSciences and TransMedics Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pressure BioSciences	$1.98 million	0.01	-$29.31 million	($0.96)	0.00
TransMedics Group	$635.89 million	3.75	$190.29 million	$4.40	15.67

TransMedics Group has higher revenue and earnings than Pressure BioSciences. Pressure BioSciences is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Pressure BioSciences and TransMedics Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pressure BioSciences	0	0	0	0	0.00
TransMedics Group	0	6	6	0	2.50

TransMedics Group has a consensus price target of $135.00, suggesting a potential upside of 95.85%. Given TransMedics Group’s stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than Pressure BioSciences.

Volatility and Risk

Pressure BioSciences has a beta of 6.15, indicating that its share price is 515% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Pressure BioSciences on 12 of the 14 factors compared between the two stocks.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.